Is abundance of B cells the best biomarker to predict immune checkpoint inhibitor response in head and neck squamous cell cancers?
Ann Oncol
.
2025 Jan 10:S0923-7534(25)00007-9.
doi: 10.1016/j.annonc.2025.01.003.
Online ahead of print.
Authors
J L Low
1
,
W Q Chong
1
,
B C Goh
2
Affiliations
1
National University Cancer Institute Singapore.
2
National University Cancer Institute Singapore; Cancer Science Institute Singapore, National University of Singapore; Department of Pharmacology, Department of Medicine, National University Singapore. Electronic address:
[email protected]
.
PMID:
39800105
DOI:
10.1016/j.annonc.2025.01.003
No abstract available
Publication types
Editorial